Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
暂无分享,去创建一个
L. Jeong | M. Noh | Jung-Ae Kim | Seungchan An | Gyudong Kim | L. Pham | Hongseok Choi | Mai-Thao Nguyen | Young Eum Hyun | Y. Nguyen
[1] Ji Won Kim,et al. Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators. , 2020, Journal of medicinal chemistry.
[2] Maximilian Kuhn,et al. Assessment of Binding Affinity via Alchemical Free-Energy Calculations , 2020, J. Chem. Inf. Model..
[3] G. Miller,et al. Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues , 2020, Molecules.
[4] M. Minden,et al. Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia , 2019, Haematologica.
[5] N. Tan,et al. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence , 2019, International journal of molecular sciences.
[6] M. Bauer,et al. Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes. , 2019, Journal of medicinal chemistry.
[7] S. Suh,et al. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ , 2018, Scientific Reports.
[8] K. Jacobson,et al. Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential. , 2017, Journal of medicinal chemistry.
[9] M. Bowman,et al. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ , 2017, Proceedings of the National Academy of Sciences.
[10] Fabien Zoulim,et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases , 2013, Nature Reviews Drug Discovery.
[11] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[12] E. Balaraman,et al. Mitsunobu and related reactions: advances and applications. , 2009, Chemical reviews.
[13] C. Mathé,et al. L-nucleoside enantiomers as antivirals drugs: a mini-review. , 2006, Antiviral research.
[14] Andy Vinter,et al. Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation , 2006, J. Chem. Inf. Model..
[15] G. Maga,et al. Antivirals at the mirror: the lack of stereospecificity of some viral and human enzymes offers novel opportunities in antiviral drug development. , 2003, Current drug targets. Infectious disorders.
[16] H. Choo,et al. L-nucleosides: antiviral activity and molecular mechanism. , 2002, Current topics in medicinal chemistry.
[17] Khalil Bennis,et al. A new route to some enantiomerically pure substituted morpholines from d-ribono- and d-gulono-1,4-lactones , 1994 .
[18] O. Mitsunobu,et al. Preparation of Esters of Carboxylic and Phosphoric Acid via Quaternary Phosphonium Salts , 1967 .
[19] F. Šorm,et al. Nucleic acids components and their analogues. LIII. Preparation of 1-2'-deoxy-β-L-ribofuranosylthymine, L-thymidine , 1964 .